Search
Edodekin alfa
go.drugbank.com/drugs/DB15631Investigational, or Cannot Be Removed by Surgery). … Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic
Efpeglenatide
go.drugbank.com/drugs/DB15650InvestigationalAlone or in Combination With Oral Antidiabetic Drug(s)). … Efpeglenatide is under investigation in clinical trial NCT03713684 (Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin
Nanoparticle Epirubicin
go.drugbank.com/drugs/DB16248InvestigationalNanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma).
Vonlerolizumab
go.drugbank.com/drugs/DB16352InvestigationalVonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic
Dialyzable leukocyte extract
go.drugbank.com/drugs/DB16530InvestigationalTransferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator. … It is thought to have widespread effects on the immune system, and effective in treating infections and immunological issues.
Camibirstat
go.drugbank.com/drugs/DB21586InvestigationalCamibirstat has a monoisotopic molecular weight of 562.17 Da. … Camibirstat is under investigation in clinical trial NCT04891757 (FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies).
R1204
go.drugbank.com/drugs/DB05118ExperimentalR1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Icotinib
go.drugbank.com/drugs/DB11737Investigationalicotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of
MEM 1414
go.drugbank.com/drugs/DB05888ExperimentalIt appears to work in the area of the brain where new memories are formed. … MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials.
LIC-477
go.drugbank.com/drugs/DB05363ExperimentalLIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.